ArticleOncogene2015
Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer.
Article in Oncogene, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 81 citations in OpenAlex.
- Athymic murine models can underestimate the immune-dependent components of chemotherapy efficacy.Frontiers in immunology · 2026Review
- Molecular Subtyping and Therapeutic Targeting of IFNG-Driven Immunogenic Cell Death in Lung Adenocarcinoma.Cancer medicine · 2025Article
- Sensitize Tumor Immunotherapy: Immunogenic Cell Death Inducing Nanosystems.International journal of nanomedicine · 2024Review
- Effects of Electrochemotherapy on Immunologically Important Modifications in Tumor Cells.Vaccines · 2023Article
- Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review.Frontiers in pharmacology · 2023Review
- Gut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma.Frontiers in immunology · 2023Review
- Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer.Nature communications · 2022Article
- Science-Driven Nutritional Interventions for the Prevention and Treatment of Cancer.Cancer discovery · 2022Article
- Anti-cancer activity of human gastrointestinal bacteria.Medical oncology (Northwood, London, England) · 2022Review
- Immunostimulatory effects of vitamin B5 improve anticancer immunotherapy.Oncoimmunology · 2022Article
- Metabolic features of cancer cells impact immunosurveillance.Journal for immunotherapy of cancer · 2021Article
- Proteomics, Personalized Medicine and Cancer.Cancers · 2021Review
- The Microbiome and Its Implications in Cancer Immunotherapy.Molecules (Basel, Switzerland) · 2021Review
- Pyridoxal kinase and poly(ADP-ribose) affect the immune microenvironment of locally advanced cancers.Oncoimmunology · 2021Article
- Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data.OncoTargets and therapy · 2021Review
- Immunogenic Cell Death and Elimination of Immunosuppressive Cells: A Double-Edged Sword of Chemotherapy.Cancers · 2020Review
- Review
- Article
- Sequential Interferon β-Cisplatin Treatment Enhances the Surface Exposure of Calreticulin in Cancer Cells via an Interferon Regulatory Factor 1-Dependent Manner.Biomolecules · 2020Article
- Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.Journal for immunotherapy of cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
cis-Diamminedichloroplatinum(II) (CDDP), which is mostly referred to as cisplatin, is a widely used antineoplastic. The efficacy of cisplatin can be improved by combining it with the vitamin B6 precursor pyridoxine. Here, we evaluated the putative synergistic interaction of CDDP with pyridoxine in the treatment of an orthotopic mouse model of non-small-cell lung cancer (NSCLC). CDDP and pyridoxine exhibited hyperadditive therapeutic effects. However, this synergy was only observed in the context of an intact immune system and disappeared when the otherwise successful drug combination was applied to the same NSCLC cancer implanted in the lungs of athymic mice (which lack T lymphocytes). Immunocompetent mice that had been cured from NSCLC by the combined regimen of CDDP plus pyridoxine became resistant against subcutaneous rechallenge with the same (but not with an unrelated) cancer cell line. In vitro, CDDP and pyridoxine did not only cause synergistic killing of NSCLC cells but also elicited signs of immunogenic cell death including an endoplasmic reticulum stress response and exposure of calreticulin at the surface of the NSCLC cells. NSCLC cells treated with CDDP plus pyridoxine in vitro elicited a protective anticancer immune response upon their injection into immunocompetent mice. Altogether, these results suggest that the combined regimen of cisplatin plus pyridoxine mediates immune-dependent antineoplastic effects against NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.